刘超美, 薛克昌, 姚嘉勇, 姜元英, 陆波, 吴义杰. 6-(4′-取代酰胺基苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物的合成及其抑制血小板聚集作用J. 药学学报, 1999, 34(1): 23-28.
引用本文: 刘超美, 薛克昌, 姚嘉勇, 姜元英, 陆波, 吴义杰. 6-(4′-取代酰胺基苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物的合成及其抑制血小板聚集作用J. 药学学报, 1999, 34(1): 23-28.
Liu Chaomei, Xue Kechang, Yao Jiayong, Jiang Yuanying, Lu Bo , Wu Yijie, . SYNTHESIS AND PLATELET AGGREGATION INHIBITORY ACTIVITY OF 6-(4′-SUBSTITUTED ACYLAMINOPHENYL)-4,5-DIHYDRO-3-(2H)-PYRIDAZINONESJ. Acta Pharmaceutica Sinica, 1999, 34(1): 23-28.
Citation: Liu Chaomei, Xue Kechang, Yao Jiayong, Jiang Yuanying, Lu Bo , Wu Yijie, . SYNTHESIS AND PLATELET AGGREGATION INHIBITORY ACTIVITY OF 6-(4′-SUBSTITUTED ACYLAMINOPHENYL)-4,5-DIHYDRO-3-(2H)-PYRIDAZINONESJ. Acta Pharmaceutica Sinica, 1999, 34(1): 23-28.

6-(4′-取代酰胺基苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物的合成及其抑制血小板聚集作用

SYNTHESIS AND PLATELET AGGREGATION INHIBITORY ACTIVITY OF 6-(4′-SUBSTITUTED ACYLAMINOPHENYL)-4,5-DIHYDRO-3-(2H)-PYRIDAZINONES

  • 摘要: 目的:6-(4′-取代苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物的合成及抗血小板聚集活性的研究。方法:通过付-克反应、碳链延长、水解和环合反应得到两个关键中间体,然后通过酰化反应制得各种酰胺化合物;参考Born比浊法测定目标化合物的抗血小板聚集活性。结果:设计合成了24个6-(4′-取代酰胺基苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物,22个为首次报道;所有化合物在体外对ADP诱导的兔血小板聚集均有不同程度的抑制作用,第II类化合物的抑制作用强于第I类化合物,其中I1,I3,II1,II3,II4,II6和II9的抑制作用均强于对照药CI-930,其中II1和II3的抑制作用最强,其IC50约为CI-930的1/10。结论:其中一些化合物显示较强的抗血小板聚集活性,值得进一步研究。

     

    Abstract: AIM: To study the synthesis and antiplatelet aggregation activity of 6-(4′-substituted acyl aminophenyl)-4,5-dihydro-3(2H)-pyridazinones. METHODS: The title compounds were synthesized by acylation of twelve acyl chlorides and two intermediates prepared by Friedel-Crafts reaction, lengthening of carbon chain, hydrolysis and cyclization; the antiplatelet aggregation activity of the title compounds was measured by Born′s method. RESULTS: Twenty four 6-(4′-substituted acyl aminophenyl)-4,5-dihydro-3(2H)-pyridazinones were designed and synthesized. Of them, 22 were first reported. The chemical structures of all the compounds were determined by IR, 1HNMR and elementary analysis. The intermediate, 6-(4′-aminophenyl)-4,5-dihydro-3(2H)-pyridazinones, was synthesized by two methods. Preliminary pharmacological tests showed that all of the title compounds inhibited ADP induced platelet aggregation to a certain extent. Compounds II showed more potent inhibition than did compounds I. The inhibitory activities of I1, I3, II1, II3, II4, II6 and II9, were more potent than that of the control compound CI-930. The inhibitory effect of II1 and II3 against platelet aggregation were about ten times of that of CI-930. CONCLUSION: Some of the title compounds showed potent activity of antiplatelet aggregation and should be studied further.

     

/

返回文章
返回